Navigation Links
AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
Date:3/4/2013

o-controlled design, this pivotal Phase 3 study enrolled 178 adult patients at 13 U.S. sites for the treatment of acute post-operative pain immediately following major abdominal surgery.  Patients were treated for post-operative pain for a minimum of 48 hours, and up to 72 hours.  Patients were randomized 2:1, with 119 patients randomized to sufentanil and 59 to placebo treatment.  Both treatments were delivered by the patient, as needed, using the NanoTab System with a 20-minute lock-out period.  Patients in both groups could receive up to 2 mg morphine intravenously per hour as a rescue medication, the primary purpose of this rescue medication being to provide placebo-treated patients access to pain medication to enable them to stay in the study as long as possible.  Pre-rescue pain scores were imputed to minimize the impact of this rescue opioid on efficacy evaluations.

Eighty, or 70.2% of the sufentanil NanoTab-treated patients completed the 48-hour study period, compared to 30 (51.7%) placebo-treated patients.  Reasons for drop-out in the sufentanil- and placebo-treated groups were adverse events (5.3% and 6.9% respectively), lack of efficacy (16.7% and 31.0% respectively) and other (7.9% and 10.3% respectively).  The primary endpoint measure, SPID-48, was 105.6 for sufentanil-treated patients and 55.6 for placebo-treated patients (p=0.001). 

Treatment-emergent adverse events occurred in 64.0% of sufentanil-treated patients and 67.2% of placebo-treated patients.  Adverse events with an occurrence greater than 5% in either the sufentanil group or the placebo group were nausea (30.7% and 41.4% respectively), fever (14.9% and 8.6% respectively), vomiting (8.8% and 6.9% respectively), itching (8.8% and 0.0% respectively), oxygen saturation decrease (6.1% and 1.7% respectively), and hypertension (2.6% and 5.2% respectively).  Itching, a frequently observed side effect of opioids, was the only adverse e
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. AcelRx Pharmaceuticals Provides Clinical Trial Updates
3. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
4. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
6. AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
7. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
8. AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
9. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
10. AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012
11. AcelRx Pharmaceuticals Hires Mike A. Royal, M.D. as Chief, Clinical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013 Apama Medical, a privately ... of next-generation atrial fibrillation technologies, today announced the ... US Patent and Trademark Office (USPTO), titled "Low ... assemblies for use on expandable structures such as ... procedures. "We are grateful to the ...
(Date:6/17/2013)... 17, 2013 Velplex, LLC announced this week ... platform that connects buyers and sellers of discount ... leader. Why? It,s because the business ... familiar with the dental industry. They have 50 years ... diligently worked to negotiate some of the best prices ...
(Date:6/17/2013)... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... a preliminary prospectus supplement to its effective shelf registration statement ... with securities regulatory authorities in each of the provinces of ... offering of its common shares to raise gross proceeds of ... also grant to the underwriters of the Offering an option, ...
Breaking Medicine Technology:TopProdeals.com Rises to Top as Discount Dental Supply Leader 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4
(Date:6/18/2013)... have discovered and mapped the signaling network between two ... could cut off cancer cell growth at its starting ... University of Texas MD Anderson Cancer Center reported the ... cancer drug target, and MCM7, a protein vital to ... issue of Cancer Cell . , "MCM7 overexpression ...
(Date:6/18/2013)... Two months ago, Suyima Torres, 28, died from ... session of a silicone treatment for gluteus augmentation at Cuerpos ... performed by a mystery Venezuelan doctor in a center that ... Bernabe Vazquez of Bayshore Cosmetic Surgery , women suffering ... are not board certified is more common than people think. ...
(Date:6/18/2013)... Calif. (PRWEB) June 18, 2013 David ... professor of Family Medicine for the College of Osteopathic ... Health Sciences has been elected president of the ... Edmund G. Brown Jr. appointed Connett, a 1984 alumnus ... OMBC members recently elected Connett to the position during ...
(Date:6/18/2013)... People with HIV are more likely to keep their ... if they feel their physician listens, explains things ... a "case," new Johns Hopkins research suggests. , "If ... to them, they feel that doctor has their best ... follow medical advice," says study leader Tabor E. Flickinger, ...
(Date:6/18/2013)... of investigators co-led by Weill Cornell Medical College is ... research, similar to the kind of risk and benefit ... no dynamic research framework to systematically detect devices and ... may even be harmful," says co-lead investigator Dr. Art ... the June 18 issue of the British Medical ...
Breaking Medicine News(10 mins):Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3Health News:Respect may be the key to stopping patient 'no shows' 2Health News:Tackling a framework for surgical innovation 2Health News:Tackling a framework for surgical innovation 3
... ... SRI International, an independent nonprofit research and development institute, announced ... its Center for Health Sciences. This new SRI group of neuroscientists and ... of funding from the National Institutes of Health (NIH), including the ...
... , LAVAL, QC and ... Inc. (TSX: DDS; NASDAQ: DDSS ) today announced the closing ... units were sold at a price of US$1.70 per ... were US$18,150,000 after deducting underwriting discounts and commissions, and ...
... how human genes interact with their environment to boost ... edition of the American Journal of Human Genetics ... for specific gene variants linked to human diseases can ... genes and environmental factors influence common human diseases like ...
... the battlefield, a new UCLA study of U.S. Civil War ... units characterized by a strong esprit de corps were much ... heart condition than veterans from less cohesive companies, two UCLA ... expect your buddy to have your back," said Dora Kosta, ...
... ... of IT Infrastructure , ... Reston, VA (PRWEB) February 18, 2010 -- Carahsoft Technology Corp. , the trusted ... provider of extreme-scale grid computing software and services. Carahsoft is placing Parabon ...
... ... team, names Estelle Cummings as Area Vice-President of Sales , ... Cambridge, MD (PRWEB) February 18, 2010 -- ... V.P. of Sales for the CCBsure®, technology program . Cummings oversees new ...
Cached Medicine News:Health News:SRI International Expands Neurosciences Research with New Neurodegenerative Diseases Research Program 2Health News:SRI International Expands Neurosciences Research with New Neurodegenerative Diseases Research Program 3Health News:SRI International Expands Neurosciences Research with New Neurodegenerative Diseases Research Program 4Health News:SRI International Expands Neurosciences Research with New Neurodegenerative Diseases Research Program 5Health News:SRI International Expands Neurosciences Research with New Neurodegenerative Diseases Research Program 6Health News:Labopharm announces closing of US$20 million public offering of units 2Health News:Labopharm announces closing of US$20 million public offering of units 3Health News:UCLA study reveals how genes interact with their environment to cause disease 2Health News:Battlefield camaraderie yields long-term dividends for veterans, study finds 2Health News:Battlefield camaraderie yields long-term dividends for veterans, study finds 3Health News:Battlefield camaraderie yields long-term dividends for veterans, study finds 4Health News:Parabon's Frontier Grid Platform Software Now Available on Carahsoft's GSA Schedule 2Health News:Parabon's Frontier Grid Platform Software Now Available on Carahsoft's GSA Schedule 3Health News:CCBsure Names New Area Vice-President of Sales 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: